Status:
COMPLETED
Study to Assess Relative Bioavailability of BMS-986435 Formulations in Healthy Adult Participants
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Healthy Participants
Eligibility:
All Genders
18-60 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to assess the relative bioavailability of BMS-986435 tablet formulations in healthy adult male and female participants.
Eligibility Criteria
Inclusion
- Body weight of ≥ 45 kg and a body mass index (BMI) between 18 and 32 kg/m\^2, inclusive.
- Healthy as determined by medical history, physical examination, vital signs, 12-lead electrocardiogram (ECG) and clinical laboratory assessments.
- Have documented left ventricular ejection fraction (LVEF) ≥ 60% and absence of significant cardiac abnormality.
Exclusion
- Any acute or chronic medical illness.
- History of heart disease.
- Prior exposure to BMS-986435.
- Other protocol-defined Inclusion/Exclusion criteria apply.
Key Trial Info
Start Date :
September 3 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 19 2025
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT06577259
Start Date
September 3 2024
End Date
February 19 2025
Last Update
March 14 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution - 0001
San Antonio, Texas, United States, 78209